SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Sensitive Detection of DJ-1 in Artificial Cerebrospinal Fluid Using a Portable GPTMS-Coordinated Gold Nanoparticle-Based Biosensor.

Biosensors (Basel) · 2026-03-03

DOI: 10.3390/bios16030146PMID: 41892038

Open accessresearch-article; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

A highly selective and sensitive compact immunosensing strategy was developed for the determination of DJ-1, a potential biomarker of Parkinson's disease, one of the leading neurodegenerative disorders, using a portable potentiostat. Initially, screen-printed carbon electrodes (SPCEs) were modified with gold nanoparticles (AuNPs), followed by functionalization with 4-mercapto-1-butanol (MOH). Subsequently, the AuNPs-doped and hydroxyl-functionalized electrodes were treated with 3-glycidoxypropyltrimethoxysilane (GPTMS) to facilitate immobilization of anti-DJ-1 antibodies. Immobilization steps were monitored using electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV) performed on a bench potentiostat, while the entire analytical performance of the developed biosensor system and its response in artificial cerebrospinal fluid (aCSF) were evaluated by monitoring cathodic current changes with a portable electrochemical reader. The resulting biorecognition element enabled the detection of DJ-1 within the concentration range of 0.001 to 0.3 ng/mL, based on cathodic current changes, achieving a limit of detection as low as 0.00059 ng/mL. Surface morphology and elemental composition alterations were characterized by scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), and energy-dispersive X-ray spectroscopy (EDX). A notable advantage of this GPTMS@AuNPs-based biosensor system is its prolonged storage stability and its capability to accurately quantify DJ-1 in artificial cerebrospinal fluid samples, with recovery rates ranging from 98.66% to 123.3%.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.